-
Most Recent
Search Results
240 results for MER
Investors Should View IBIO Stock Among Vaccine Wanna-be’s, Not Makers
IBIO stock has been acting like a potential COVID-19 vaccine producer, but it lacks contracts with leading providers and its own work remains at a…
Novavax Is the Ultimate Coronavirus Stock
Novavax has failed at late-stage clinical trials before, but if its COVID-19 vaccine even has 50% efficacy it could open up a huge global opportunity.
4 Big, Safe Dividend Plays for the Long Haul
Dividend ETFs are popular with investors, as they seek better performance than bonds provide. Here are four ETFs for the long haul.
5 Best Vanguard Funds to Buy for Target Date 2030 Retirement
You’re going to need some added oomph if you’ve got roughly 15-20 years before retirement. Here’s a look at some of the best Vanguard funds…
3 Cult-Like Stocks to Buy for Long-Term Gains
There are stocks and then there are cult-like stocks. These three are in the latter category for many reasons including making you money.
Capital Destruction Paves Way for Further Losses
Once in a lifetime events are piling up so fast that we are going to need several lifetimes to absorb them. Someday we’ll look back…
Will the Support Hold?
Our indicators and charts are telling us that the market is testing its support at Dow 8,000 and S&P 500 800.
Novavax Stock Rises as UK Covid Vax Okay Sought, Other Growth Anticipated
Novavax stock offers a unique opportunity to invest in a late stage biotech built on cutting-edge vaccine technology, NVAX stock has surged on its Covid-19…
Moderna Faces Tough Threats in the Short and Long Term
Moderna is facing meaningful short-term and longer-term threats. As a result, investors should sell MRNA stock at this point.
Novavax Stock Looks Like It’s a Solid Bet on a Coronavirus Vaccine
While it’s no guarantee that NVAX stock will be the ultimate winner from a Covid-19 vaccine, investors should pay attention to Novavax.
Without Positive Vaccine News, Novavax May Fall Further
NVAX stock is likely to stay under further pressure until it can release more positive clinical data
Merck Could Be the Covid-19 Investment You’re Missing
Some traders consider Merck stock to be a safe Dow Jones type of investment. Yet, the Covid-19 vaccine angle could propel the share price.
If You Like Alibaba Stock, these 3 ETFs Make Perfect Sense
While Alibaba stock is enticing, you may want to consider ETFs that have meaningful exposure to it. That way, if something goes wrong, your entire…
Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild
NVAX stock has been among the hottest stocks in 2020, but it still remains a risky investment
Inovio Pharmaceuticals Is Hurting From Remdesivir but It’s Still Standing
With White House health advisor Dr. Anthony Fauci’s endorsement of Gilead Sciences’ remdesivir, INO stock now seems irrelevant. But that might not be accurate if…
Why Science and Economics Might Justify CureVac
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust…
5 Weird Mutual Funds Worth Your Investment
Most mutual funds use some kind of industry-standard stock selection methodology. A few like to do their own thing. Here are four worth considering.
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
NVAX stock’s prospects in November depend upon regulatory developments regarding its Covid-19 vaccine candidate
As Optimism Wanes, the Ride May Be Over for Novavax stock
Novavax has been one of the companies cashing in on the race to find a vaccine against COVID-19. As a result NVAX stock is up…
6 – 10 of 240 results
